Amgen laying off 121 workers in Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
More housing key to health of tri-county economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Forecast: Ventura County economy to contract further in 2017
Ventura County’s economy is expected to contract further in 2017, declining by nearly 1 percentage point. That is the prediction of the California Lutheran University Center for Economic Research and Forecasting, which will present its forecast on Oct. 26. The CERF report says the dominant economic story to emerge in Ventura County over the past Read More →
Ventura County economic development plan approved
Ventura County’s Board of Supervisors has approved the first economic development plan in the history of the county. The board voted 5-0 to approve the countywide “Economic Vitality Strategic Plan” at its board meeting on Oct. 24. Officials said the plan was the product of four public sessions and was designed to “foster economic growth Read More →
Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.